You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-AA-24-002: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R41/R42 Clinical Trials Not Allowed)

    Release Date: 12-21-2023Open Date: 03-05-2024Due Date: 04-09-2024Close Date: 04-10-2024

    Drug development is challenging, particularly for Central Nervous System (CNS) medications. It takes approximately 18 years to move a potential CNS medication from its initial discovery phase to the marketplace, often costing several billion dollars. The failure rate is high (only 8% of new CNS compounds entering Phase I studies will reach the market) and contributes to the high costs and slow rat ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAR-23-268: Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed

    Release Date: 04-18-2023Open Date: 05-06-2023 Due Dates: Multiple Close Date: 06-07-2025

    Purpose This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I and Phase II (Fast track) grant applications. The funding opportunity will utilize a UT1/UT2 cooperative agreement to support SBCs to propose the development of novel extracellular vesicle (EV)-based therapeutic platforms for ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PAR-23-267: Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)

    Release Date: 04-18-2023Open Date: 05-06-2023 Due Dates: Multiple Close Date: 06-07-2025

    Purpose This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I and Phase II (Fast track and Direct to phase II) grant applications. The funding opportunity will utilize a U43/U44 cooperative agreement to support SBCs to propose the development of novel extracellular vesicle-based therape ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAR-23-213: Interactive Digital Media (IDM) Biomedical Science Resources for Pre-College Students and Teachers (SBIR) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 06-15-2023Open Date: 08-05-2023 Due Dates: Multiple Close Date: 09-06-2025

    Interactive Digital Media (IDM) refers to products and services on digital computer-based systems which respond to the user’s actions by presenting content in the form of text, images, animations, audios, videos, and video games. These products and services have been widely used in science, technology, engineering, and mathematics (STEM) education to enrich student's learning experience both ins ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-22-103: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)

    Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024

    Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-22-102: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)

    Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024

    Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PAR-23-032: Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

    Release Date: 10-27-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-06-2025

    Purpose This Funding Opportunity Announcement (FOA) encourages the translation of technology and therapeutic innovations from academic and other non-profit research sectors to the marketplace to advance the development of diagnostic and prevention tools or treatments for musculoskeletal, rheumatic, or skin diseases. Small Business Concerns (SBCs) are encouraged to apply for this Small Business In ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-TR-23-018: Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2- Clinical Trial Not Allowed)

    Release Date: 11-22-2023Open Date: 01-22-2024 Due Dates: Multiple Close Date: 02-24-2026

    This Notice of Funding Opportunity (NOFO) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, Phase II, and Fast-Track grant applications. The funding opportunity will utilize a UT1/UT2 cooperative agreement to support small business concerns (SBCs) to propose applications to create bench top, portable, automated, self-containe ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. RFA-TR-23-017: Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)

    Release Date: 11-22-2023Open Date: 01-22-2024 Due Dates: Multiple Close Date: 02-24-2026

    This Notice of Funding Opportunity (NOFO) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I, Phase II, Fast-Track and Direct to Phase II grant applications. The funding opportunity will utilize a U43/U44 cooperative agreement to support small business concerns (SBCs) to propose applications to create bench top, portable, autom ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-24-066: NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)

    Release Date: 11-30-2023Open Date: 12-01-2023 Due Dates: Multiple Close Date: 01-08-2027

    This Notice of Funding Opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NEI. This program provides support for milestone-driven, commercialization-oriented clinical trials and will involve participation of NEI program ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government